MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/31/2017 04:04 PDT] MNKD Expected to Trade Up After Bullish Patterns Develop
• [05/26/2017 11:16 PDT] MannKind Corp (NASDAQ:MNKD), Up By 50.00% ($0.56) From $1.120 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions